21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 10.04.2026 Expectation: 500 pips
AUDCAD flashes short-term buy signal
Today at 11:27 AM 15
Period: 10.04.2026 Expectation: 800 pips
GBPUSD is poised to resume decline after short-term bullish momentum
Today at 11:23 AM 11
Period: 29.05.2026 Expectation: 2000 pips
Selling USDCAD with 1.37250 target
Today at 10:06 AM 9
Period: 30.04.2026 Expectation: 1300 pips
Investing in SPX during correction with 6,700 in sight
Today at 07:33 AM 9
Brent sell
Period: 10.04.2026 Expectation: 850 pips
Brent crude pullback is coming as geopolitical premium fades
Today at 06:51 AM 16
Period: 30.04.2026 Expectation: 850 pips
Selling EURUSD down to 1.1490
Today at 04:12 AM 12
Go to forecasts